Blood biomarkers predicting adverse clinical outcomes in congenital heart disease patients, with consideration for pulmonary valve replacement Cover

.blurhash-client-img { display: none !important; }

Blood biomarkers predicting adverse clinical outcomes in congenital heart disease patients, with consideration for pulmonary valve replacement

Acta Marisiensis - Seria Medica

Volume 69 (2023): Issue 1 (March 2023)

By: Milla Marika Kainlauri and Irina-Bianca Kosovski

Open Access

|Mar 2023

Authors

Milla Marika Kainlauri

milli.k@outlook.com

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania

Irina-Bianca Kosovski

Department of Pathophysiology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania

DOI: https://doi.org/10.2478/amma-2023-0009 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755

Journal RSS Feed

Language: English

Page range: 11 - 16

Submitted on: Oct 20, 2022

|

Accepted on: Feb 14, 2023

|

Published on: Mar 29, 2023

Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

congenital heart disease,

tetralogy of Fallot,

pentalogy of Fallot,

blood biomarkers,

pulmonary valve replacement

Related subjects:

Clinical medicine,

Clinical medicine, other

© 2023 Milla Marika Kainlauri, Irina-Bianca Kosovski, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous article Volume 69 (2023): Issue 1 (March 2023)Next article